Advanced Research in Hypertrophic Cardiomyopathy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 31 March 2025 | Viewed by 85
Special Issue Editors
Interests: hypertrophic cardiomyopathy; the role of myosin inhibitors in positive cardiac remodeling; valvular heart disease research
Interests: cardiology research; research methodologies and biostatistics
Interests: clinical cardiology; myocardial infarction; cardiovascular genetics; clinical electrophysiology; molecular cardiology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue will focus on everything new in the risk stratification and management of hypertrophic cardiomyopathy, addressing the following:
- New trends in the treatment of hypertrophic cardiomyopathy (HCM) and the role of myosin inhibitors;
- Advantages and disadvantages of traditional and new therapies for HCM: septal reduction therapy vs. myosin inhibitors;
- Risk of arrhythmias while on myosin inhibitors;
- Treatment on the horizon for hypertrophic cardiomyopathy beyond myosin inhibitors;
- Gene therapy for hypertrophic cardiomyopathy;
- Contemporary trends in the risk stratification of sudden cardiac death in HCM;
- New research on understanding the genetic nature of HCM, focusing on the management and follow up of patients with genetically positive/phenotypically negative HCM profiles.
Dr. Said Alsidawi
Dr. Juan Maria Farina
Dr. Celestino Sardu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hypertrophic cardiomyopathy
- myosin inhibitors
- genetic therapy
- risk stratification
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
